Nemucore Microscope Ovarian Cancer Patient and Doctor MRI

Meet Leslie, a 42-year-old mother of three children aged 2, 5, and 7. Leslie's oncologist has just informed her that she has Stage III Ovarian Cancer.

Leslie has a 25% chance of living to see her youngest child’s 7th birthday. Women like Leslie represent the challenge and opportunity for the transformation of ovarian cancer therapies. Many of these women develop multi-drug resistant cancers. This is when cancer cells develop attributes that resist multiple drugs due to a number of mutations in the cell that limit the effectiveness of current treatment regimens. Finding solutions to this challenge represents a chance to extend the life of women like Leslie.

Nemucore Medical Innovations Inc is a clinical development oncology company with a strong focus on creating innovative therapies for women’s cancers. We are dedicated to the development and commercialization of life-saving molecularly targeted therapies for the treatment of multi-drug resistant cancers.

Nemucore is actively partnering with scientists at leading institutions who are addressing aggressive cancers and developing ways to identify which patients will benefit from new products we are creating and provide patients with life-threatening cancers, like Leslie, a new hope.